Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

被引：12
|
作者：
Johnson, B. [1 ]
Miller, V. [2 ]
Amler, L. [3 ]
Stern, H. [3 ]
Soh, C. [3 ]
O'Connor, P. [3 ]
Kabbinavar, F. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(09)72037-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Miller, V. A.
    Das, A.
    Rossi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Miller, V. A.
    O'Connor, P.
    Soh, C.
    Kabbinavar, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [3] ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Johnson, Bruce E.
    Kabbinavar, Fairooz
    Fehrenbacher, Louis
    Hainsworth, John
    Kasubhai, Saifuddin
    Kressel, Bruce
    Lin, Chin-Yu
    Marsland, Thomas
    Patel, Taral
    Polikoff, Jonathan
    Rubin, Mark
    White, Leonard
    Yang, James Chih-Hsin
    Bowden, Chris
    Miller, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3926 - +
  • [4] Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Kabbinavar, F. F.
    Miller, V. A.
    Johnson, B. E.
    O'Connor, P. G.
    Soh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)
    Kabbinavar, Fairooz
    Fehrenbacher, Louis
    Hainsworth, John
    Kasubhai, Saifuddin
    Kressel, Bruce
    Marsland, Thomas
    Patel, Taral
    Rubin, Mark
    White, Leonard
    Yang, James Chih-Hsin
    Klughammer, Barbara
    Colburn, Dawn
    Miller, Vincent
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : 1411 - 1417
  • [6] A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)
    Sandler, A.
    Schiller, J. H.
    Hirsh, V.
    Sequist, L. V.
    Soria, J.
    Von Pawel, J.
    Wang, Q.
    Pande, A. U.
    Schwartz, B. E.
    Garmey, E. G.
    Gorbatchevsky, I.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small cell lung cancer: Correlative analyses
    Spigel, David R.
    Burris, Howard A.
    Greco, F. Anthony
    Shipley, Diana L.
    Friedman, Elke K.
    Waterhouse, David M.
    Whorf, Robert C.
    Mitchell, R. Brian
    Daniel, Davey B.
    Zangmeister, Jeffery
    Hainsworth, John D.
    CANCER RESEARCH, 2010, 70
  • [8] Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC)
    Faoro, L.
    Cohen, E. E.
    Govindan, R.
    Kozloff, M. F.
    Hoffman, P. C.
    Maitland, M. L.
    Verel, K.
    Szeto, L.
    Salgia, R.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
    Herbst, Roy S.
    Stern, Howard
    Amler, Lukas
    Otterson, Gregory
    Lin, Ming
    O'Connor, Paula
    Hainsworth, John
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S323 - S323
  • [10] Biomarker evaluation in the Phase Ill, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
    Herbst, Roy
    Stern, Howard
    Amler, Lukas
    Otterson, Gregory
    Lin, Ming
    O'Connor, Paula
    Hainsworth, John
    CANCER RESEARCH, 2009, 69
12345